Drug intelligence / Profile preview

chunxuean

Development stage: Unknown
Lead developer: Tianjin Pharmaceutical Da Ren Tang Group
Modality: Small Molecules
Administration: Oral

Overview

Chunxuean (春血安) is a proprietary traditional Chinese medicine (TCM) developed and manufactured by Tianjin Hong Ren Tang Pharmaceutical. It is formulated as an oral capsule and is primarily indicated for blood regulation disorders, specifically gynecological conditions such as functional uterine bleeding, menorrhagia (excessive menstrual bleeding), and metrorrhagia (irregular uterine bleeding). According to TCM theory, the medication works by cooling the blood, clearing heat, and resolving blood stasis to achieve hemostasis. It is an approved pharmaceutical product in China, frequently used in clinical practice to manage abnormal uterine bleeding patterns.

Brand names: 春血安Chunxuean
Other names: Chunxuean Capsules春血安胶囊

Beyond the preview

Go deeper on chunxuean.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chunxuean.

Explore the full profile